Yahoo Finance Arcturus Therapeutics Holdings Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
Arcturus Therapeutics Holdings (NASDAQ:ARCT) Full Year 2023 Results
Key Financial Results
Revenue: US$166.8m (down 19% from FY 2022).
Net loss: US$29.7m (down by 418% from US$9.35m profit in FY 2022).
US$1.12 loss per share (down from US$0.35 profit in FY 2022).
ARCT Products In Clinical Trials
Phase I: 1.
Phase II: 1.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Arcturus Therapeutics Holdings EPS Beats Expectations, Revenues Fall Short
Revenue missed analyst estimates by 2.2%. Earnings per share (EPS) exceeded analyst estimates by 44%.
Looking ahead, revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's shares are down 1.5% from a week ago.
Balance Sheet Analysis
Just as investors must consider earnings, it is also important to take into account the strength of a company's balance sheet. We have a graphic representation of Arcturus Therapeutics Holdings' balance sheet and an in-depth analysis of the company's financial position.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
